natgillin/translations-raw huggingface dataset:
Transaminase increases were reversible upon dose reduction or interruption.
Zvišanje ravni aminotransferaz je bilo reverzibilno po zmanjšanju odmerka ali prekinitvi zdravljenja.
Transaminase, ALKP and bilirubin levels should be investigated before the initiation of the combination treatment with Vargatef plus docetaxel.
Ravni transaminaz, ALKP in bilirubina je treba določiti pred uvedbo kombiniranega zdravljenja z zdravilom Vargatef in docetakselom.
Transaminases
povečane vrednosti
Transaminases
povišane vrednosti
Transaminases
transaminaz
Transaminases
zvečana vrednost
Transaminases increased
povečane vrednosti trasaminaz
transaminases increased
zvečana koncentracije aminotransferaz
Transaminases increased
zvišana aktivnost transaminaz
transaminases increased
zvišana koncentracija transaminaz
Transaminases increased
zvišana raven transaminaz
Transaminases increased
zvišana vrednost transaminaz
Transaminases increased
zvišane ravni transaminaz
Transaminases increased
zvišane transaminaze
Transaminases increased
zvišane vrednosti transaminaz
Transaminases increased
zvišanje transaminaz
Transaminases increased (AST/ALT)
Zvišanje transaminaz (AST/ALT)
Transaminases increased Gallstones
zvišane vrednosti transaminaz žolčni kamni
Transaminases increased, aspartate aminotransferase increased, gamma- glutamyltransferase increased, liver function test abnormal, blood alkaline phosphatase increased, blood bilirubin increased
povečanje vrednosti aminotransferaz, povečanje vrednosti aspartat- aminotransferaze, povečanje vrednosti gama-glutamiltransferaze, nenormalni izvidi testov delovanja jeter, povečanje vrednosti alkalne fosfataze v krvi, povečanje vrednosti bilirubina v krvi
Transaminases increased.
zvišana vrednost transaminaz
TRANSCEND randomized ACE-I intolerant patients with otherwise similar inclusion criteria as ONTARGET to telmisartan 80 mg (n = 2954) or placebo (n = 2972), both given on top of standard care.
V študiji TRANSCEND, ki je imela sicer podobna merila za vključitev kot študija ONTARGET, so bolnike, ki niso prenesli zaviralca ACE, randomizirali na 80 mg telmisartana (n = 2954) ali placebo (n = 2972); enega in drugega so bolniki prejemali poleg standardne oskrbe.
TRANSCEND randomized ACE-I intolerant patients with otherwise similar inclusion criteria as ONTARGET to telmisartan 80 mg (n=2954) or placebo (n=2972), both given on top of standard care.
V študijo TRANSCEND so bolnike razvrstili po metodi naključne izbire na podlagi podobnih vključitvenih meril, kot so jih uporabili v študiji ONTARGET, in sicer so zdravili bolnike, ki ne prenašajo zaviralcev ACE.
Transcriptase Inhibitors (NNRTIs) (e.g., delavirdine, nevirapine)*
Drugi nenukleozidni zaviralci reverzne transkriptaze (NNRTIs) (kot sta delavirdin, nevirapin)
Transdermal
(papir/folija/Bar
Transdermal administration of oxybutynin bypasses the first-pass gastrointestinal and hepatic metabolism, reducing the formation of the N-desethyl metabolite.
Pri transdermalni uporabi oksibutinin obide presnovo prvega prehoda skozi prebavila in jetra, zato se zmanjša nastanek N- dezetilnega presnovka.
Transdermal patch
Transdermalni obliž
Transdermal patch
Transdermalni obliž.
Transdermal patch adhesive: acrylate-vinylacetate copolymer
Lepilo transdermalnega obliža: akrilno-vinilacetatni kopolimer
transdermal patches
transdermalna obliža
Transdermal patches
transdermalni obliži
Transdermal solution
transdermalna raztopina
Transdermal solution.
Transdermalna raztopina
Transdermal solution.
Transdermalna raztopina.
Transdermal use
ex® laminat)
Transdermal use Week 4
4. teden
Transdermal versus oral contraceptives
Transdermalni kontraceptivi v primerjavi s peroralnimi
transfer + 1 venipuncture set + 1 syringe + 2 swabs
za vensko punkcijo + 1 brizga + 2
Transfer 1.0 ml of air into the solvent vial, then withdraw 1.0 ml of water for injections from the solvent vial using the syringe provided in the kit.
S pomočjo brizge, ki je priložena v kompletu, najprej v vialo z vehiklom iztisnite 1,0 ml zraka, nato pa iz nje izvlecite 1,0 ml vode za injekcije.
Transfer all the diluent to the vial.
Ves vehikel prenesite v vialo.
Transfer diluent from syringe to the vial by pushing the plunger in all the way
Vehikel prenesite v vialo tako, da pritisnete bat do konca.
Transfer from basal insulin
Prehod z zdravljenja z bazalnim insulinom
Transfer from GLP-1 receptor agonist therapy
Prehod z zdravljenja z agonistom receptorjev GLP-1
Transfer the appropriate volume of reconstituted solution of Metalyse into the syringe, based on the patient’s weight.
V brizgo prenesemo ustrezen volumen pripravljene raztopine zdravila Metalyse, določen glede na bolnikovo telesno maso.
Transfer the concentrate into a sterile, evacuated glass bottle or intravenous bag (PVC or non- PVC).
Koncentrat prenesite v sterilno, izpraznjeno intravensko infuzijsko steklenico ali vrečko (PVC ali ne-PVC tipa).
Transfer the concentrate into a sterile, evacuated glass bottle or IV bag (PVC or non-PVC).
Koncentrat prenesite v sterilno, izpraznjeno intravensko infuzijsko steklenico ali vrečko (PVC ali ne-PVC tipa).
Transfer the content of the glass vial into the bag of diluent.
Prenesite vsebino stekleničke v vrečko z vehiklom.
Transfer the implant to the outlet of the catheter.
Implantat prenesite na izhodno odprtino katetra.
Transfer the Ingelvac CircoFLEX vaccine into the vaccine bottle of Ingelvac MycoFLEX.
Prenesite vsebino plastenke s cepivom Ingelvac CircoFLEX v plastenko s cepivom Ingelvac MycoFLEX.
Transfer the solution back into the cartridge using the transfer set.
Raztopino s setom za prenos prenesite nazaj v vložek.
Transfer the solution by pushing on the plunger slowly until all of the solution in the oral dosing syringe is transferred to a glass or cup for administration (e.g. if your doctor told you to dissolve two Kuvan tablets in 40 ml water and administer 30 ml to your child, you would have to use the 20 ml oral dosing syringe two times to draw up 30 ml (e.g.
Raztopino prenesite tako, da bat počasi potiskajte navzdol, dokler vse raztopine v peroralni odmerni brizgi ne prenesete v kozarec ali skodelico za dajanje (npr. če vam je zdravnik povedal, da raztopite dve tableti zdravila Kuvan v 40 ml vode in otroku dajte 30 ml, morate 20 ml peroralno odmerno brizgo uporabiti dvakrat, da izvlečete 30 ml (npr.
Transfer the suspension into the diluent (Do not use if cloudy).
Suspenzijo prenesite v vehikel (Ne uporabite, če je vsebina motna).
Transfer the suspension into the diluent.
Suspenzijo prenesite v vehikel (Ne uporabite, če je vsebina motna).
Transfer the suspension into the solvent bag.
Prenesite suspenzijo v vrečko topila.
Transfer the suspension to an amber glass or amber polyethyleneterephthalate (PET) bottle.
Prenesite suspenzijo v temno obarvano stekleno ali temno obarvano polietilen tereftalat (PET) steklenico.
transfer to
ODMEREK
Transfer to Xultophy from doses of basal insulin < 20 and > 50 units has not been studied.
Prehoda z zdravljenja z bazalnim insulinom v odmerkih, manjših od 20 enot in večjih od 50 enot, na zdravljenje z zdravilom Xultophy niso raziskali.
Transferring a patient to another type or brand of insulin
Prehod bolnika na drugo vrsto ali blagovno znamko insulina
Transferring a patient to another type or brand of insulin should be done under strict medical supervision.
Prehod bolnika na drugo vrsto ali blagovno znamko insulina mora potekati pod strogim zdravniškim nadzorom.
Transferring patients from immediate-release cysteamine bitartrate hard capsules
Prehod bolnikov s trdih kapsul s takojšnjim sproščanjem, ki vsebujejo cisteaminijev bitartrat
Transformation at 60 months, n/N (%)
Transformacija v 60. mesecu, n/N (%)
Transformation to leukaemia or myelodysplastic syndrome
Preobrazba v levkemijo ali mielodisplatični sindrom
Transfusion Independence (≥ 182 days) #
Neodvisnost od transfuzij (≥ 182 dni) #
Transfusion Independence (≥ 56 days) #
Neodvisnost od transfuzij (≥ 56 dni) #
Transfusion of 2 or more units of packed red blood cells or whole
Transfuzija dveh ali več enot koncentriranih eritrocitov ali polne krvi
Transfusion of 4 or more units of blood over a 48 hour period
Transfuzija 4 ali več enot krvi v obdobju 48 ur
Transfusion reaction, Fractures*, Rigors*, Face injury, Joint injury*, Burns, Laceration, Procedural pain, Radiation injuries*
reakcije na transfuzijo, zlomi#, okorelost*, poškodbe obraza, poškodbe sklepov*, opekline#, raztrganine, bolečina pri posegu, poškodbe pri obsevanju
Transfusion reaction, Fractures*, Rigors*, Face injury, Joint injury*, Burns, Laceration, Procedural pain, Radiation injuries*
reakcije na transfuzijo, zlomi*, okorelost*, poškodbe obraza, poškodbe sklepov*, opekline, raztrganine, bolečina pri posegu, poškodbe pri obsevanju
Transfusion related acute lung injury
transfuzijo povezana akutna okvara pljuč
Transfusion-related acute lung injury
transfuzijo povezana akutna poškodba pljuč
Transfusions
transfuzije
Transient antibodies against Leishmania detected by immunofluorescence antibody test (IFAT) may appear after vaccination.
Po cepljenju se lahko razvijejo prehodna protitelesa proti patologiji Leshmania, ki jih odkrije imunofluorescenčni test za ugotavljanje protiteles (IFATPIFT).
Transient apathy and fever (above 39.5 °C) may occur.
Lahko se pojavita pojavita prehodna apatija in povišana telesna temperatura (nad 39° C).
Transient apathy and hyperthermia (above 39.5 °C) may occur.
Lahko se pojavita prehodna apatija in povišana telesna temperatura (nad 39° C).
Transient bradycardia
prehodna bradikardija
Transient but fully reversible infertility in male rats was associated with migalastat treatment at all doses assessed.
Prehodna, vendar v celoti reverzibilna neplodnost pri podganjih samcih se je izrazila pri vseh ocenjevanih odmerkih.
transient corneal opacity
začasna motnost roženice
Transient cosmetic effects such as wet hair and a white dry residue may occur at the application site and may persist up to 7 days; however, these effects are usually not noticeable after 48 hours.
Na mestu nanosa se lahko pojavijo prehodni kozmetični učinki kot so mokra dlaka in beli suhi ostanki, ki lahko ostanejo do 7 dni; vendar ti učinki navadno niso več opazni v 48 urah.
Transient cytogenetic abnormalities have been observed in normal donors following G-CSF use.
Pri običajnih darovalcih, ki so prejemali faktor, ki spodbuja rast granulocitnih kolonij, so opazili prehodne citogenetske nenormalnosti.
Transient cytogenetic abnormalities have been observed in normal donors following G-CSF use.
Pri zdravih dajalcih, ki so prejemali G-CSF, so opazili prehodne citogenetske spremembe.
Transient cytogenic modifications have been observed in normal donors following G-CSF use.
Pri običajnih darovalcih, ki so prejemali faktor, ki spodbuja rast granulocitnih kolonij, so opazili prehodne citogenetske spremembe.
Transient decrease of testosterone concentrations
prehodno zmanjšanje koncentracije testosterona
Transient ECG changes such as T-wave flattening, S-T segment depression and benign arrhythmias are not considered mandatory indications for the cessation of Myocet therapy.
Prehodne spremembe EKG, kot so izravnavanje vala T, depresija segmenta S-T in benigne aritmije, niso nujne indikacije za prekinitev zdravljenja z zdravilom Myocet.
Transient elevation in liver enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase) has been observed shortly after the first infusion of Gazyvaro.
Kmalu po prvi infuziji zdravila Gazyvaro so opažali prehodno zvišanje jetrnih encimov (aspartat- aminotransferaze [AST], alanin-aminotransferaze [ALT], alkalne fosfataze).
Transient elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), bilirubin and white blood cell count may occur with sevoflurane, as with the use of other halogenated anaesthetic agents.
Tako kot pri uporabi drugih halogeniranih anestetikov se lahko pri sevofluranu pojavi prehodno zvišanje aspartatne aminotransferaze (AST), alaninske aminotransferaze (ALT), laktatne dehidrogenaze (LDH), bilirubina in števila belih krvničk.
Transient elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), bilirubin and white blood cell counts may occur with sevoflurane, as with the use of other halogenated anaesthetic agents.
Tako kot pri uporabi drugih halogeniranih anestetikov se lahko pri sevofluranu pojavi prehodno zvišanje aspartatne aminotransferaze (AST), alaninske aminotransferaze (ALT), laktatne dehidrogenaze (LDH), bilirubina in števila belih krvničk.
Transient elevations in CSF protein and white blood cells have been observed in patients following DepoCyte administration, and have also been noted after intrathecal treatment with methotrexate or cytarabine.
Prehodna povišanja vrednosti beljakovin v likvorju ter belih krvnih celic so opazili pri bolnikih po dajanju zdravila DepoCyte, kot tudi po intratekalnem zdravljenju s citarabinom in metotreksatom.
Transient elevations in total bilirubin >3 x ULN (mostly indirect) occurred in 17 (27.0%) subjects; 15 of these subjects were receiving atazanavir.
Prehodna zvišanja celokupnega bilirubina (v glavnem indirektnega) na > 3-kratno ZNM so se pojavila pri 17 (27,0 %) preiskovancih; 15 teh preiskovancev je prejemalo atazanavir.
Transient episodes of hypertonia and/or severe muscular weakness that prevent voluntary movements may occur at any time during treatment.
Kadar koli v poteku zdravljenja lahko nastopijo tudi prehodne epizode oz. napadi hipertonije in/ali hude mišične šibkosti, ki preprečujejo hotne gibe.
Transient erythema, pruritus or other signs of discomfort at the application site have been reported rarely and usually disappear spontaneously, within 24 hours following administration of the product.
Redko se lahko na mestu nanosa pojavi prehodna rdečina, praskanje ali drugi znaki neugodja, ki navadno spontano izginejo znotraj 24 ur po nanosu.
Transient fever was observed in rare cases.
V redkih primerih je bila opažena kratkotrajna povišana telesna temperatura.
transient flu-like symptoms, such as aching muscles, generally feeling unwell and sometimes with fever usually at the start of treatment, taste disturbance.
prehodni gripi podobni simptomi, kot npr. bolečine v mišicah, splošno slabo počutje in včasih zvišana telesna temperatura, običajno ob začetku zdravljenja motnje okusa
Transient hypercholesterolaemia, transient hypertriglyceridaemia
prehodna hiperholesterolemija, prehodna hipertrigliceridemija
Transient hypertension has been observed primarily during the loading dose in association with the peripheral vasoconstrictive effects of dexmedetomidine and a loading dose is not recommended.
Predvsem pri uporabi udarnega odmerka v povezavi s perifernimi vazokonstriktornimi učinki deksmedetomidina so opazili prehodno hipertenzijo, zato uporaba udarnega odmerka ni priporočljiva.
Transient increase in serum creatinine may be greater in patients with underlying impaired renal function.
Pri bolnikih s predhodno zmanjšanim delovanjem ledvic je lahko prehodno zvišanje koncentracije kreatinina v serumu bolj izrazito.
Transient inhibition of P-gp by
Tipranavir/r najprej prehodno
Transient ischaemic attack
prehodna možganska ishemija
Transient ischaemic attack, Seizure*, Seizure recurrence*, Syncope
tranzitorni ishemični napad, konvulzije,* ponavljajoče konvulzije,* sinkopa
transient ischaemic attacks
tranzitorne ishemične atake
Transient ischaemic attacks and cerebrovascular accident
Prehodni ishemični napadi in cerebrovaskularni inzult
transient ischemic attack (mini stroke)
prehodni ishemični napad (mini kap)
Transient ischemic attack, cerebral vascular accident
prehodna ishemična ataka, cerebrovaskularni insult
Transient lethargy and hyperthermia may occur for 1 day, exceptionally 2 days.
Lahko se pojavita prehodna letargičnost in povišana temperatura, ki lahko trajata en dan in le izjemoma dva dni.
Transient local injection site reactions, which are restricted to a slight swelling (< 2 cm diameter), may uncommonly occur and disappear within 1 day.
Prehodne lokalne reakcije na mestu injiciranja, ki so omejene na rahlo oteklino (s premerom < 2 cm), se redko pojavijo in izginejo v 1 dnevu.
Transient local reactions at the application site (erythema and/or pruritus) can occur in very rare cases (less than 1 in 10,000 animals).
Prehodne lokalne reakcije (eritem in/ali pruritus) se lahko na mestu aplikacije pojavijo v zelo redkih primerih (pri manj kot 1 od 10.000 živali).
Transient local reactions at the application site (erythema and/or pruritus) can occur in very rare cases (less than 1 in 10,000 animals).
Prehodne lokalne reakcije (eritem in/ali pruritus) se lahko na mestu dajanja pojavijo v zelo redkih primerih (pri manj kot 1 od 10.000 živali).
Transient local reactions at the injection site may occur after vaccination mainly in the form of a hard, warm and sometimes painful swelling (diameter up to 10 cm).
Po cepljenju se lahko na mestu vboda pojavijo prehodne lokalne reakcije, večinoma v obliki trde, tople in včasih boleče otekline (premera do 10 cm).
Transient local reactions at the injection site may occur after vaccination mainly in the form of a hard, warm and sometimes painful swelling (diameter up to 10 cm).
Po cepljenju se lahko na mestu vboda pojavijo prehodne lokalne reakcije, večinoma v obliki trdne, tople in včasih boleče otekline (premera do 10 cm).
Transient local reactions may occur after the administration of one dose of vaccine.
Po uporabi enega odmerka cepiva pride lahko do prehodnih lokalnih reakcij.
Transient loss of consciousness, paraesthesia
atrijska aritmija, hipotenzija, bradikardija
transient low blood pressure, vascular disorders (which can cause pain, redness and swelling in the limbs)
prehoden nizek krvni tlak; žilne bolezni (zaradi katerih so vaše okončine lahko boleče, pordele in otekle)
transient low blood pressure; pain and swelling of the joints, similar to gout.
prehoden nizek krvni tlak, bolečina in oteklost sklepov.
Transient mild digestive tract disorders (e.g. hypersalivation, vomiting) were observed in very rare cases.
V zelo redkih primerih se lahko pojavijo prehodne lažje prebavne motnje (n.pr. povečano slinjenje, bruhanje).
Transient mild neurological disorders (e.g. tremors, incoordination) were observed in very rare cases.
V zelo redkih primerih se lahko pojavijo prehodne lažje nevrološke motnje (n.pr. drhtenje, nekontrolirani gibi).
Transient muscular tremors, incoordination and depression were occasionally observed when the veterinary product was administered at overdoses of up to 5 times the recommended dose.
Pri zaužitju 5-kratnega terapevtskega odmerka se je občasno pojavilo prehodno mišično drgetanje, ataksija in potrtost.
Transient mydriasis, salivation, vomiting and transient rapid respiration were observed.
Mladičem so se razširile zenice, slinili so se in bruhali, dihanje je bilo pospešeno.
Transient neurological symptoms that may mimic MS exacerbations may occur following injections.
Po injekcijah se lahko pojavijo prehodni nevrološki simptomi, ki so lahko podobni poslabšanju oz. izbruhu multiple skleroze.
Transient ocular changes (see Clinical experience).
prehodne očesne spremembe (glejte Klinične izkušnje)
Transient oligospermia
Prehodna oligospermija
Transient platelet response was defined as weekly platelet count ≥ 50 x 109/l for 4 or more times during study weeks 2-25 but without durable platelet response.
Prehodni odziv trombocitov je bil opredeljen kot tedensko število trombocitov ≥ 50 x 109/l, ugotovljeno 4- ali večkrat od 2. do 25. tedna, a brez trajnega odziva.
Transient profound oligospermia has been reported following exposure to 6–mercaptopurine in combination with corticosteroids.
Po izpostavljenosti 6-merkaptopurinu v kombinaciji s kortikosteroidi so poročali o prehodni močni oligospermiji.
Transient replicons carrying NS5A or NS5B from patient isolates.
Prehodni replikoni ki nosijo NS5A ali NS5B,iz izolatov bolnikov,
Transient skin redness, itching or other signs of discomfort at the application site have been reported rarely and usually disappear without any treatment and within 24 hours after using the medicine.
Redko se lahko na mestu nanosa pojavi prehodna rdečina, praskanje ali drugi znaki neugodja, ki navadno spontano izginejo znotraj 24 ur po nanosu zdravila za uporabo v veterinarski medicini.
Transient stinging or burning may occur when the cream is applied to abraded or broken skin.
Če zdravilo nanesete na poškodovano kožo, se lahko na mestu nanosa pojavi prehoden pekoč občutek.
Transient swelling at the injection site following administration may occur.
Malo število zdravljenih živali kaže škodljive reakcije v obliki otekline na mestu dajanja.
transient symptoms as in an acute-phase response (myalgia, malaise and rarely, fever), typically in association with initiation of treatment†
prehodni simptomi kot pri akutni reakciji (mialgija, oslabelost in redko zvišana telesna temperatura), značilno za začetek zdravljenja
Transient thrombocytopenia
prehodna trombocitopenija
Transient thrombocytopenia (platelets < 100 x 109/L) following filgrastim administration and leukapheresis was observed in 35 % of subjects studied.
Pri 35 % oseb, ki so sodelovale v preskušanju, so po odmerjanju filgrastima in po levkaferezi opazili prehodno trombocitopenijo (št. trombocitov < 100 x 109/l).
Transient thrombocytopenia (platelets < 100 x 109/l) following filgrastim administration and leukapheresis was observed in 35% of subjects studied.
Prehodno trombocitopenijo (število trombocitov < 100 x 109/l) po dajanju filgrastima in levkaferezi so ugotovili pri 35 % preučevanih oseb.
Transient thrombocytopenia, transient lymphadenopathy
Prehodna trombocitopenija, prehodna limfadenopatija
Transient thrombocytopenia.
Prehodna trombocitopenija.
Transient visual disturbances may occur especially on initiation of treatment, due to changes in blood glucose levels.
Zaradi sprememb vrednosti glukoze v krvi se lahko pojavijo prehodne motnje vida, še posebej na začetku zdravljenja.
Transient,
Prehodna
Transient, asymptomati c elevations of hepatic aminotransfe rases (ALT, AST),
prehodna asimptomatska zvišanja jetrnih aminotransferaz (ALT, AST),
Transient, asymptomatic elevations of hepatic
Prehodna asimptomatska
Transient, asymptomatic elevations of hepatic aminotransferas es (ALT, AST),
prehodna asimptomatska zvišanja jetrnih aminotransfera
Transient, asymptomatic elevations of hepatic aminotransferas es (ALT, AST),
prehodna asimptomatska zvišanja jetrnih aminotransfera z (ALT, AST),
Transient, asymptomatic elevations of hepatic aminotransferas es(ALT, AST),
prehodna asimptomatska zvišanja jetrnih aminotransferaz (ALT, AST),
Transient, asymptomatic elevations of hepatic aminotransferase s (ALT, AST),
prehodna asimptomatska zvišanja jetrnih aminotransfera z (ALT, AST),
Transient, asymptomatic elevations of hepatic aminotransferases
Prehodna asimptomatska zvišanja jetrnih aminotransferaz (ALT, AST), posebno na
Transient, asymptomatic elevations of hepatic aminotransferases (ALT, AST),
aminotransferaz (ALT, AST),
Transient, asymptomatic elevations of hepatic aminotransferases (ALT, AST),
prehodna asimptomatska zvišanja jetrnih aminotransferaz (ALT, AST),
Transient, asymptomatic elevations of hepatic aminotransferases (ALT, AST), especially in early treatment (see section 4.4)
Prehodna asimptomatska zvišanja jetrnih aminotransferaz (ALT, AST), posebno na začetku
Transient, asymptomatic elevations of hepatic aminotransferases (ALT, AST), especially in early treatment (see section 4.4)
prehodna asimptomatska zvišanja jetrnih aminotransferaz (ALT, AST), posebno na začetku zdravljenja (glejte poglavje 4.4)
Transient, asymptomatic elevations of hepatic aminotransferases , alanine transferase (ALT), aspartate transferase (AST) have been seen commonly, especially in early treatment.
Pogosto so opažali prehodna, asimptomatska zvišanja jetrnih aminotransferaz, alaninske transferaze (ALT) in aspartatne transferaze (AST), posebno na začetku zdravljenja.
Transient, asymptomatic elevations of hepatic aminotransferases , alanine transferase (ALT), aspartatetransferase (AST) have been seen commonly, especially in early treatment.
Pogosto so opažali prehodna, asimptomatska zvišanja jetrnih aminotransferaz, alaninske transferaze (ALT) in aspartatne transferaze (AST), posebno na začetku zdravljenja.